Albert Bourla, Pfizer’s chairman and CEO, will receive the 2024 the American Association for Cancer Research Outstanding Achievement Award for Service to Cancer Science and Medicine during the AACR Annual Meeting 2024, to be held April 5-10 in San Diego, California.
The American Association for Cancer Research has named its newest class of grant recipients.
NCI renewed the University of Chicago Medicine Comprehensive Cancer Center’s “comprehensive” designation and continued grant support for another five years.
Antonio C. Wolff, chair of the Breast Cancer Committee for the ECOG-ACRIN Cancer Research Group, will co-lead the Breast Cancer Steering Committee for NCI. He began the three-year term on April 1.
Anna Berkenblit, a clinical oncologist and drug developer, was named the first-ever chief scientific and medical officer of the Pancreatic Cancer Action Network.
Jonathan Chernoff and William G. KaelinWilliam G. Kaelin Jr., physician, scientist, and Nobel laureate, was recognized at Fox Chase Cancer Center with the Stanley P. Reimann Honor Award, the center’s highest distinction.
Ellen V. Sigal, Marlene A. Malek, Scott LaGanga, and Tim Lawrence will be honored at the 36th Annual Lombardi Gala, an annual event dedicated to raising funds for Georgetown University’s Lombardi Comprehensive Cancer Center.
The FY24 Defense Appropriations Act is anticipated to provide funding for the Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members, and all women impacted by this disease.
The Society for Immunotherapy of Cancer is taking nominations for the SITC Annual Awards and the Academy of Immuno-Oncology.
Researchers from Fred Hutchinson Cancer Center, the American Cancer Society Cancer Action Network, and peer institutions released findings in the Journal of Clinical Oncology showing that when all types of cancer research studies are considered, at least one in five people with cancer, or 21.9%, participate in some form of clinical research.
